Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature (Q26798526)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2 references

1 August 2020

29 October 2020

0 references

Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

murine-derived monoclonal antibodies

22 February 2020

main subject

interstitial nephritis

7 references

13 March 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

29 October 2020

7 references

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 May 2020

1 August 2020

29 October 2020

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

1 August 2020

1 reference

29 October 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Blaithin A McMahon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paul J Scheel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Serena Bagnasco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mohamed G Atta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

1 August 2015

9 references

13 March 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

29 May 2020

1 August 2020

29 October 2020

8 references

13 March 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 August 2020

29 October 2020

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

e1366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

22 February 2020

copyright license

8 references

13 March 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 May 2020

1 August 2020

on focus list of Wikimedia project

29 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Rituximab for IgG4-related disease: a prospective, open-label trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

An update on IgG4-related disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Clinical Manifestations of IgG4-Related Disease in the Pharynx: Case Series and Review of the Literature.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Consensus statement on the pathology of IgG4-related disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Diagnosis of IgG4-related tubulointerstitial nephritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Novel use of rituximab in a case of Riedel's thyroiditis refractory to glucocorticoids and tamoxifen.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

Standard steroid treatment for autoimmune pancreatitis.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616672

The diagnostic utility of serum IgG4 concentrations in IgG4-related disease

28 November 2018

1 reference

12 December 2020

Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients

1 reference

12 December 2020

Characteristic tubulointerstitial nephritis in IgG4-related disease

1 reference

12 December 2020

Treatment approaches to IgG4-related systemic disease

1 reference

12 December 2020

Successful "medical" orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis

1 reference

12 December 2020

Cutaneous immunoglobulin G4-related systemic disease

1 reference

12 December 2020

10.1097/MD.0000000000001366

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266393%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2 references